PBAC's latest decision on Cabazitaxel: Recommended (2022). Considered for Treatment of castration resistant metastatic carcinoma of the prostate in patients previously treated with a docetaxel-containing regimen, in combination with prednisone or prednisolone.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2011
Submissions
4
2011 → 2022
Eligible population
Adults with castration resistant metastatic carcinoma of the prostate who have failed treatment with docetaxel due to resistance or intolerance, with WHO performance status of 2 or less, treated in combination with prednisone or prednisolone.
Cost-minimisation analysis; no ICER calculated. PBAC noted that cabazitaxel Accord is not expected to provide substantial and clinically relevant improvement in efficacy or reduction of toxicity over currently listed cabazitaxel brands.
ICER (historical)
$45k/QALY–$75k/QALY across 2 submissions (2011) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.